| Orthovirginia, Inc | |
|
13801 St Francis Blvd, Suite 200, Midlothian, VA 23114-3206 | |
| (804) 270-1305 | |
| (804) 273-9294 |
| Full Name | Orthovirginia, Inc |
|---|---|
| Type | Facility |
| Speciality | Clinic/center - Multi-specialty |
| Location | 13801 St Francis Blvd, Midlothian, Virginia |
| Accepts Medicare Assignments | Does not participate in Medicare Program. The facility may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1205973229 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225X00000X | Occupational Therapist | (* (Not Available)) | Secondary |
| 261QM1300X | Clinic/center - Multi-specialty | (* (Not Available)) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Orthovirginia, Inc Po Box 715868, Philadelphia, PA 19171-5868 Ph: (804) 915-1910 | Orthovirginia, Inc 13801 St Francis Blvd, Suite 200, Midlothian, VA 23114-3206 Ph: (804) 270-1305 |
News Archive
The U.S. Food and Drug Administration today allowed marketing of the Xpert MTB/RIF Assay, the first FDA-reviewed test that can simultaneously detect bacteria that cause tuberculosis and determine if the bacteria contain genetic markers that makes them resistant to rifampin, an important antibiotic for the treatment of TB.
Teenage girls with a familial or genetic risk for breast cancer worry more about getting the disease, even when their mother has no history, compared to girls their age with no known high risks, according to new data presented today by researchers from Penn Medicine's Abramson Cancer Center at the annual meeting of the American Society of Clinical Oncology in Chicago (Abstract #9527).
Cepheid today announced it has received clearance from the U.S. Food & Drug Administration (FDA) to market Xpert® SA Nasal Complete, the first and only molecular test designed for the simultaneous detection and differentiation of both Staphylococcus aureus (SA) and Methicillin-resistant Staphylococcus aureus (MRSA) colonization in less than one hour. The test runs on Cepheid's GeneXpert® System, the world's leading molecular platform for accuracy, speed, and ease-of-use.
Regulations to remove the current ban on advertising certain over the counter (OTC) medicines to the public were laid in Parliament today
The American Association of Homes and Services for the Aging (AAHSA) commends the Senate for passing Sen. Michael Bennet's (D-Colo.) amendment, which reassures seniors by protecting guaranteed benefits, and strengthens Medicare by keeping savings within the program.
› Verified 3 days ago